PNH Clinical Trial
Official title:
Phase IIa, Open Label, Multiple Dose Study to Assess the Safety, Efficacy and Pharmacokinetics of Subcutaneously Administered APL-2 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH).
This is a Phase IIa, open-label, multiple dose, study in patients with PNH who have not received eculizumab (Soliris ®) in the past. A single cohort of subjects is planned for evaluation.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04725812 -
Complement Regulation to Undo Systemic Harm in Preeclampsia
|
Phase 2 | |
Completed |
NCT02598583 -
Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
|
Phase 1/Phase 2 | |
Recruiting |
NCT05539248 -
A Study on the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of CAN106 in Subjects With PNH
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03460301 -
Observational of PNH Type Cells in Korean Patients With Bone Marrow Failure Syndrome and Having Hemolytic PNH
|
N/A | |
Completed |
NCT01412047 -
Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study
|
N/A | |
Completed |
NCT02605993 -
Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
|
Phase 2 | |
Completed |
NCT05095168 -
Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Ascending Dose (SAD) of CAN106 Administered Intravenously (IV) in Healthy Subjects
|
Phase 1 | |
Terminated |
NCT04702568 -
A Long Term Safety Study of BCX9930 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)
|
Phase 2 | |
Completed |
NCT05337683 -
A Retrospective Chart Review Study to Evaluate the Impact of Eculizumab in Korean PNH Patients
|
||
Active, not recruiting |
NCT03531255 -
Pegcetacoplan Long Term Safety and Efficacy Extension Study
|
Phase 3 | |
Not yet recruiting |
NCT06449001 -
Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis
|
Phase 3 | |
Completed |
NCT05884060 -
Retrospective Chart Review Screening Algorithm to Assess the Prevalence of PNH-clones
|
||
Available |
NCT05982938 -
Danicopan Early Access Program
|